FDA 483 - Maynard R. Rasmussen, M.D - May 06, 2022

An FDA inspection of Maynard R. Rasmussen, M.D. in San Diego, CA, a clinical investigator, identified an issue with investigational drug disposition records. The firm failed to adequately document the dates and quantities for unused maintenance doses of study drug kits for multiple subjects. This indicates a deficiency in accountability for investigational products.